Europe Breast Cancer Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), and Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies)
The Europe breast cancer therapeutics market was valued at US$ 8,446.96 million in 2022 and is expected to reach US$ 16,836.17 million by 2030; it is estimated to grow at a CAGR of 9.0% from 2022 to 2030.
Increased Support from Government and Private Organizations Fuels the Europe Breast Cancer Therapeutics Market
Governments of various countries recognize the importance of addressing breast cancer and are implementing policies to improve access to effective treatments. Many governments and private organizations have increased funding for research and development in breast cancer therapeutics, resulting in the development of innovative drugs and therapies. The European Commission Initiative on Breast Cancer (ECIBC) offers universally accessible, basic quality care at all levels. The mission of ECIBC is to give women and healthcare practitioners impartial, unbiased advice on screening and care based on the most recent scientific research. The increased investment in research has allowed pharmaceutical companies to explore new treatment options and develop highly targeted and effective therapies for breast cancer patients.
Several government bodies across the world are also taking steps to improve access to these treatments by implementing reimbursement policies and healthcare initiatives that cover the cost of breast cancer therapeutics for patients. This means that more patients can afford these treatments and have access to the latest advancements in breast cancer therapeutics. The increased government support has also created a favorable market environment for healthcare providers. With more funding and resources available, healthcare providers are able to offer their patients a wider range of treatment options. This improves patient outcomes and allows healthcare providers to stay competitive in the market. Overall, the increased support from governments and private organizations for breast cancer therapeutics has driven innovation, leading to new and improved treatments. It has also improved access to these treatments, benefiting more patients. This presents a significant opportunity for the Europe breast cancer therapeutics market growth as pharmaceutical companies and healthcare providers continue to invest in research and development activities and expand their offerings to meet the growing demand.
Europe Breast Cancer Therapeutics Market Overview
The European breast cancer therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Breast cancer is a common type of cancer in the UK. As per the National Health Service (NHS), about one in seven women are diagnosed with breast cancer during their lifespan in Great Britain data. Each year, ~55,000 women are diagnosed with breast cancer.
Greater demand from the medical industry to treat breast cancer patients with novel therapeutics has led to greater investment in R&D, fueling the growth of the market. Breast Cancer Now is the largest dedicated breast cancer research funder in the UK. To date, it has invested US$ 308.01 million (?250 million) in ground-breaking research to develop better treatment for breast cancer patients.
Additionally, the efforts of government and initiatives taken by market players have helped accelerate the growth of the breast cancer therapeutics market in the country. In November 2022, NHS rolled out an innovative and potentially life-saving breast cancer drug through a new drug deal. Pembrolizumab (Keytruda), combined with chemotherapy, reduces the chances of breast cancer progressing by almost two-fifths. The drug is delivered directly into the bloodstream every three to six weeks for over one year; the NHS funds the treatment to give access to eligible patients. It is the second new drug for triple-negative breast cancer available on the NHS, after sacituzumab govitecan (Trodelvy).
Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
Europe Breast Cancer Therapeutics Market Segmentation
The Europe breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.
Based on drug therapy, the Europe breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.
In terms of breast cancer type, the Europe breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.
By distribution channel, the Europe breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.
Based on country, the Europe breast cancer therapeutics market is categorized into Germany, France, UK, Italy, Spain, and the Rest of Europe. The UK dominated the Europe breast cancer therapeutics market in 2022.
Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are some of the leading companies operating in the Europe breast cancer therapeutics market.
Increased Support from Government and Private Organizations Fuels the Europe Breast Cancer Therapeutics Market
Governments of various countries recognize the importance of addressing breast cancer and are implementing policies to improve access to effective treatments. Many governments and private organizations have increased funding for research and development in breast cancer therapeutics, resulting in the development of innovative drugs and therapies. The European Commission Initiative on Breast Cancer (ECIBC) offers universally accessible, basic quality care at all levels. The mission of ECIBC is to give women and healthcare practitioners impartial, unbiased advice on screening and care based on the most recent scientific research. The increased investment in research has allowed pharmaceutical companies to explore new treatment options and develop highly targeted and effective therapies for breast cancer patients.
Several government bodies across the world are also taking steps to improve access to these treatments by implementing reimbursement policies and healthcare initiatives that cover the cost of breast cancer therapeutics for patients. This means that more patients can afford these treatments and have access to the latest advancements in breast cancer therapeutics. The increased government support has also created a favorable market environment for healthcare providers. With more funding and resources available, healthcare providers are able to offer their patients a wider range of treatment options. This improves patient outcomes and allows healthcare providers to stay competitive in the market. Overall, the increased support from governments and private organizations for breast cancer therapeutics has driven innovation, leading to new and improved treatments. It has also improved access to these treatments, benefiting more patients. This presents a significant opportunity for the Europe breast cancer therapeutics market growth as pharmaceutical companies and healthcare providers continue to invest in research and development activities and expand their offerings to meet the growing demand.
Europe Breast Cancer Therapeutics Market Overview
The European breast cancer therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Breast cancer is a common type of cancer in the UK. As per the National Health Service (NHS), about one in seven women are diagnosed with breast cancer during their lifespan in Great Britain data. Each year, ~55,000 women are diagnosed with breast cancer.
Greater demand from the medical industry to treat breast cancer patients with novel therapeutics has led to greater investment in R&D, fueling the growth of the market. Breast Cancer Now is the largest dedicated breast cancer research funder in the UK. To date, it has invested US$ 308.01 million (?250 million) in ground-breaking research to develop better treatment for breast cancer patients.
Additionally, the efforts of government and initiatives taken by market players have helped accelerate the growth of the breast cancer therapeutics market in the country. In November 2022, NHS rolled out an innovative and potentially life-saving breast cancer drug through a new drug deal. Pembrolizumab (Keytruda), combined with chemotherapy, reduces the chances of breast cancer progressing by almost two-fifths. The drug is delivered directly into the bloodstream every three to six weeks for over one year; the NHS funds the treatment to give access to eligible patients. It is the second new drug for triple-negative breast cancer available on the NHS, after sacituzumab govitecan (Trodelvy).
Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
Europe Breast Cancer Therapeutics Market Segmentation
The Europe breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.
Based on drug therapy, the Europe breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.
In terms of breast cancer type, the Europe breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.
By distribution channel, the Europe breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.
Based on country, the Europe breast cancer therapeutics market is categorized into Germany, France, UK, Italy, Spain, and the Rest of Europe. The UK dominated the Europe breast cancer therapeutics market in 2022.
Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are some of the leading companies operating in the Europe breast cancer therapeutics market.
1. INTRODUCTION
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. EUROPE BREAST CANCER THERAPEUTICS MARKET - KEY INDUSTRY DYNAMICS
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. BREAST CANCER THERAPEUTICS MARKET - EUROPE MARKET ANALYSIS
5.1 Europe Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
6. EUROPE BREAST CANCER THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2030 - BY DRUG THERAPY
6.1 Overview
6.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Europe Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Europe Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. EUROPE BREAST CANCER THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2030 - BY BREAST CANCER TYPE
7.1 Overview
7.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. EUROPE BREAST CANCER THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2030 - BY DISTRIBUTION CHANNEL
8.1 Overview
8.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. EUROPE BREAST CANCER THERAPEUTICS MARKET - COUNTRY ANALYSIS
9.1 Europe Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
9.1.1 Overview
9.1.2 Europe Breast Cancer Therapeutics Market, Breakdown, by key Country- Revenue (2022) (US$ Million)
9.1.3 Europe Breast Cancer Therapeutics Market, by Country, 2022 and 2030 (%)
9.1.3.1 UK
9.1.3.1.1 UK Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 UK: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 UK: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 UK: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 UK: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 UK: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Germany
9.1.3.2.1 Germany Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Germany: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Germany: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Germany: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Germany: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Germany: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 France
9.1.3.3.1 France Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 France: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 France: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 France: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 France: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 France: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.4 Italy
9.1.3.4.1 Italy Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.4.2 Italy: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.1 Italy: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.2 Italy: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.3 Italy: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.4.4 Italy: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.5 Spain
9.1.3.5.1 Spain Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.5.2 Spain: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.1 Spain: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.2 Spain: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.3 Spain: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.5.4 Spain: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.6 Rest of Europe
9.1.3.6.1 Rest of Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.6.2 Rest of Europe: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.1 Rest of Europe: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.2 Rest of Europe: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.3 Rest of Europe: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.6.4 Rest of Europe: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. BREAST CANCER THERAPEUTICS MARKET-INDUSTRY LANDSCAPE
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. COMPANY PROFILES
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. APPENDIX
12.1 About Us
12.2 Glossary of Terms
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. EUROPE BREAST CANCER THERAPEUTICS MARKET - KEY INDUSTRY DYNAMICS
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. BREAST CANCER THERAPEUTICS MARKET - EUROPE MARKET ANALYSIS
5.1 Europe Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
6. EUROPE BREAST CANCER THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2030 - BY DRUG THERAPY
6.1 Overview
6.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Europe Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Europe Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. EUROPE BREAST CANCER THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2030 - BY BREAST CANCER TYPE
7.1 Overview
7.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. EUROPE BREAST CANCER THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2030 - BY DISTRIBUTION CHANNEL
8.1 Overview
8.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. EUROPE BREAST CANCER THERAPEUTICS MARKET - COUNTRY ANALYSIS
9.1 Europe Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
9.1.1 Overview
9.1.2 Europe Breast Cancer Therapeutics Market, Breakdown, by key Country- Revenue (2022) (US$ Million)
9.1.3 Europe Breast Cancer Therapeutics Market, by Country, 2022 and 2030 (%)
9.1.3.1 UK
9.1.3.1.1 UK Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 UK: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 UK: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 UK: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 UK: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 UK: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Germany
9.1.3.2.1 Germany Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Germany: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Germany: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Germany: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Germany: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Germany: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 France
9.1.3.3.1 France Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 France: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 France: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 France: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 France: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 France: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.4 Italy
9.1.3.4.1 Italy Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.4.2 Italy: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.1 Italy: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.2 Italy: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.3 Italy: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.4.4 Italy: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.5 Spain
9.1.3.5.1 Spain Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.5.2 Spain: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.1 Spain: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.2 Spain: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.3 Spain: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.5.4 Spain: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.6 Rest of Europe
9.1.3.6.1 Rest of Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.6.2 Rest of Europe: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.1 Rest of Europe: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.2 Rest of Europe: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.3 Rest of Europe: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.6.4 Rest of Europe: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. BREAST CANCER THERAPEUTICS MARKET-INDUSTRY LANDSCAPE
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. COMPANY PROFILES
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. APPENDIX
12.1 About Us
12.2 Glossary of Terms
